Cyclerion Therapeutics 就 Cyc-126 二期概念验证研究取得进展:获FDA反馈并成立临床顾问委员会

美股速递
Feb 17

生物制药公司 Cyclerion Therapeutics, Inc. 近日宣布,其在研药物 Cyc-126 的二期概念验证研究取得了重要进展。公司已获得美国食品药品监督管理局的反馈,并正式组建了临床顾问委员会,为后续临床开发计划的推进奠定了坚实基础。

这一系列举措标志着 Cyc-126 项目的开发进入了一个新的关键阶段。获得监管机构的指导性意见,有助于优化试验设计。而顶尖专家团队的加入,将为研究提供宝贵的科学和临床见解。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10